Silk Road Medical Names Chas McKhann as CEO

November 2, 2023—Silk Road Medical, Inc. announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately.

Silk Road Medical, which is located in Sunnyvale, California, and Plymouth, Minnesota, markets the Enroute transcarotid stent for transcarotid artery revascularization (TCAR). Used in conjunction with the Enroute transcarotid neuroprotection system during the TCAR procedure, the Enroute stent is FDA approved for patients at high risk and standard risk for complications from carotid endarterectomy.

On October 10, the company announced that CEO Erica Rogers would retire from the company after the completion of a succession process. McKhann succeeds Rogers, who has now retired from the President and CEO role and will continue as an advisor to the company’s Board of Directors.

According to Silk Road Medical, McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, McKhann served as President and CEO of Apollo Endosurgery, a company focused on minimally invasive technologies for gastrointestinal and bariatric conditions. Apollo was acquired by Boston Scientific in April 2023. Previously, McKhann held leadership positions at Torax Medical and Intersect ENT, among others.

“I am thrilled to join Silk Road Medical as the company’s CEO,” stated McKhann in the company’s press release. “I look forward to working closely with the leadership team and Board of Directors to build upon Silk Road’s track record of growth, advance the company’s progress toward establishing TCAR as the minimally invasive standard of care in carotid artery disease, and continue delivering on the company’s mission to reduce the risk of stroke and its devastating impact for patients.”

Jack Lasersohn, Chairman of the Board of Directors of Silk Road, commented in the press release, “Chas is a skilled and experienced leader with a track record of effectively building and scaling medical device businesses into underpenetrated markets. We are excited to welcome him to Silk Road. We thank Erica Rogers for her leadership and contributions to Silk Road over the last 11 years, and we look forward to our next phase of growth as we continue expanding the use of TCAR.”

Lasersohn continued, “The Board and I are confident that Chas is the right leader to leverage our strong operational infrastructure, skilled commercial team, and substantial body of clinical evidence to take the company further on the journey to treat patients with carotid artery disease. Under his leadership, Silk Road remains committed to the same mission, vision, and values that have guided it since its founding. We look forward to executing a smooth transition and continue expanding our impact for patients at risk of stroke.”